Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292)

Rick Greene, MD, discusses with Margaret Kemeny, MD, the results of a phase III randomized trial that evaluated the effect of perioperative fluorouracil on overall survival in colon cancer. Dr. Kemeny is author of, "Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292)." Dr. Kemeny is Director of New York's Cancer Center of Excellence at Queens Cancer Center of NYC Health+Hospitals/Queens and Professor of Surgery at the Icahn School of Medicine at Mount Sinai. http://doi.org/10.1245/S10434-022-12705-8